Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study aims to unravel mysteries of common inflammatory condition in older adults

NCT ID NCT07132164

Knowledge-focused Sponsor: University Hospital, Brest Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study will follow 400 people recently diagnosed with polymyalgia rheumatica, a condition causing shoulder and hip pain. Researchers will track symptoms, treatments, and outcomes over 5 years to better understand the disease and improve diagnosis. Participants will provide blood and stool samples for analysis.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could improve how doctors diagnose and manage polymyalgia rheumatica, potentially reducing misdiagnosis and guiding better treatment plans.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly test new therapies. Results may take years and might not change practice immediately.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 400 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Jul 2035

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients agreeing to take part in the study and meeting the inclusion and non-inclusion criteria will be referred to the nearest rheumatology department participating in the study

Ages

50 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age greater than or equal to 50, with no upper age limit * Inflammatory shoulder +/- hip pain * Abnormal CRP (≥10mg/L) * Patients for whom the referring rheumatologist accepts the diagnosis of PPR after carrying out the assessment corresponding to his or her current practice * Patients for whom the referring rheumatologist has indicated that corticosteroid therapy should be started in the strict context of PPR or as background treatment for PPR. * Symptoms have progressed for 24 weeks or less Exclusion Criteria: * Presence, at the time of diagnosis, of symptoms and/or signs suggesting a diagnosis of associated giant cell arteritis * Immuno-induced PPR * Patients receiving immunosuppressive treatment with methotrexate or immunotherapy targeting interleukin-6 at inclusion. * Patients who have received corticosteroid therapy for more than 30 days or a cumulative dose of more than 500 mg of Prednisone equivalent in the month preceding the screening visit. * Patients with another chronic condition requiring long-term corticosteroid therapy or repeated courses of corticosteroids. * Patients not affiliated to a social security scheme * Patients unable to consent or unable or unwilling to complete their corticosteroid dose monitoring record. * Pregnancy * Patients under guardianship, curatorship or safeguard of justice

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Inflammatory rheumatism are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

polymyalgia rheumatica rheumatic disorder rheumatic fever

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Inflammatory rheumatism Polymyalgia rheumatica

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    30 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • AP-HP Bichat

    Paris, 75018, France

  • AP-HP Cochin

    Paris, 75014, France

  • AP-HP La Pitié-Salpétrière

    Paris, 75013, France

  • APHP - Kremlin-Bicêtre

    Le Kremlin-Bicêtre, 94270, France

  • Besançon-CIC

    Besançon, 25000, France

  • CH Boulogne/mer

    Boulogne-sur-Mer, 62321, France

  • CH Dax

    Dax, 40107, France

  • CH La Roche s/ Yon

    La Roche-sur-Yon, 85925, France

  • CH Le Havre

    Montivilliers, 76290, France

  • CH Le Mans

    Le Mans, 72037, France

  • CH Morlaix

    Morlaix, 29672, France

  • CHU Besançon

    Besançon, 25030, France

  • CHU Marseille AP-HM

    Marseille, 13009, France

  • CHU Rouen

    Rouen, Rouen, 76038, France

  • CHU Saint-Etienne

    Saint-Priest-en-Jarez, 42270, France

  • CHU Strasbourg

    Strasbourg, 67098, France

  • CHU de Bordeaux Pellegrin

    Bordeaux, 33076, France

  • CHU de Brest

    Brest, 29609, France

  • CHU de Caen

    Caen, 14033, France

  • CHU de Clermont-Ferrand

    Clermont-Ferrand, 63003, France

  • CHU de Dijon

    Dijon, 21000, France

  • CHU de Lille

    Lille, 59037, France

  • CHU de Montpellier

    Montpellier, 34295, France

  • CHU de Nice

    Nice, 06000, France

  • CHU de Toulouse

    Toulouse, 31059, France

  • CHU de Tours

    Tours, 37044, France

  • Clinique Ambroise Paré-Toulouse

    Toulouse, 31000, France

  • Clinique de l'Infirmerie Protestante de Lyon

    Caluire-et-Cuire, 69300, France

  • Hopital NOVO - Site Pontoise

    Pontoise, 95300, France

  • Institut catholique de Lille

    Lomme, 59160, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.